Buy Jyothy Labs; target of Rs 145: Angel Broking

“Jyothy Laboratories Ltd. (JLL) (standalone) reported healthy set of numbers for 1QFY2013, with revenue posting a growth of 70.6% yoy to Rs210cr, 11.7% higher than our estimate of Rs188cr. The operating margin saw an improvement of 302bp yoy to 11.9% for the quarter; however, it saw a dip of 479bp sequential basis, mainly because of increase in employee cost and other expense. Moreover, the contribution of low margin segments - Exo and Maxo - in the total sales is higher which has also impacted the operating margin on qoq basis. The company reported growth of 25.7% yoy in its profit, which came in at Rs18cr.”

“Henkel India (HIL) reported modest set of numbers for 1QFY2013. The topline grew by 14.2% on sequential basis mainly on the back of increase in realization (~10%) across the product portfolio and volume growth (~4%) with an operating margin of 10.2%. It posted a loss of Rs3cr in 1QFY2013 vis-à-vis a loss of Rs8cr in 1QFY2012 aided by margin expansion. We expect JLL’s consolidated revenue to post a CAGR of 26.8% to Rs1,468cr with an operating margin of 10.4% and profit to post a CAGR of 61.6% to Rs116cr over FY2012-14E. We maintain Buy on JLL with an SOTP target price of Rs145,” says Angel Broking research report. 

Institutional holding more than 40% in Indian cos    

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.